[1]
Porter, P. “Westernizing” women’s risks? Breast cancer in lower-income countries. New England Journal of Medicine., 2008, 358(3), 213-216.
[2]
Morgan, D.O. The Cell Cycle: Principles of Control, 1st ed 2007; New Science Press: London, .
[3]
Lee, M.G.; Nurse, P. Complementation used to clone a human homologue of the fission yeast cell cycle control gene cdc2. Nature, 1987, 327(6117), 31-35.
[4]
Peyressatre, M.; Prével, C.; Pellerano, M.; Morris, M.C. Targeting cyclin-dependent kinases in human cancers: From small molecules to peptide inhibitors. Cancer, 2015, 7, 179-237.
[5]
Weroha, S.J.; Lingle, W.L.; Hong, Y.; Li, S.A.; Li, J.J. Specific overexpression of cyclin E·CDK2 in early pre-invasive and primary breast tumors in female ACI rats induced by estrogen. Horm. Cancer, 2010, 1, 34-43.
[6]
Rossi, A.G.; Sawatzky, D.A.; Walker, A.; Ward, C.; Sheldrake, T.A.; Riley, N.A.; Caldicott, A.; Martinez-Losa, M.; Walker, T.R.; Duffin, R.; Gray, M.; Crescenzi, E.; Martin, M.C.; Brady, H.J.; Savill, J.S.; Dransfield, I.; Haslett, C. Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis. Nat. Med., 2006, 12(9), 1056-1064.
[7]
Senderowicz, A.M. Flavopiridol the first cyclin-dependent kinase inhibitor in human clinical trials. Invest. New Drugs, 1999, 17(3), 313-320.
[8]
Dholakia, S.P.; Patel, S.A. Review: Novel heterocycles and targets for cancer therapy. Am. J. Pharm. Tech. Res., 2012, 2(2), 204-226.
[9]
Lesyk, R.; Vladzimirska, O.; Holota, S.; Zaprutko, L.; Gzella, A. New 5-substituted thiazolo[3,2-b][1,2,4]triazol-6-ones: Synthesis and anticancer evaluation. Eur. J. Med. Chem., 2007, 42(5), 641-648.
[10]
Havrylyuk, D.; Zimenkovsky, B.; Vasylenko, O.; Zaprutko, L.; Gzella, A.; Lesyk, R. Synthesis of novel thiazolone-based compounds containing pyrazoline moiety and evaluation of their anticancer activity. Eur. J. Med. Chem., 2009, 44(4), 1396-1404.
[11]
Kaminskyy, D.; Zimenkovsky, B.; Lesyk, R. Synthesis and in vitro anticancer activity of 2,4-azolidinedione-acetic acids derivatives. Eur. J. Med. Chem., 2009, 44(9), 3627-3636.
[12]
Merino, P.; Tejero, T.; Unzurrunzaga, F.J.; Franco, S.; Chiacchio, U.; Saita, M.G.; Iannazzo, D.; Piperno, A.; Romeo, G. An efficient approach to enantiomeric isoxazolidinyl analogues of tiazofurin based on nitrone cycloaddition. Tetrahedron Asymmetry, 2005, 16(23), 3865-3876.
[13]
Franchetti, P.; Grifantini, M. Nucleoside and non-nucleoside IMP dehydrogenase inhibitors as antitumor and antiviral agents. Curr. Med. Chem., 1999, 6(7), 599-614.
[14]
Popsavin, M.; Torović, L.; Svircev, M.; Kojić, V.; Bogdanović, G.; Popsavin, V. Synthesis and antiproliferative activity of two new tiazofurin analogues with 2′-amido functionalities. Bioorg. Med. Chem. Lett., 2006, 16(10), 2773-2776.
[15]
Samrat, D.; Shyam, J.G.; Asish, K.S. Silver trifluoromethanesulfonate and metallic copper mediated syntheses of 1,2,3-triazole-O- and triazolyl glycoconjugates: Consecutive glycosylation and cyclization under one-pot condition. Tetrahedron Lett., 2016, 57(29), 3086-3090.
[16]
dos Anjos, J.V.; Filho, R.A.W.N.; do Nascimento, S.C.; Srivastava, R.M.; de Melo, S.J.; Sinou, D. Synthesis and cytotoxic profile of glycosyl–triazole linked to 1,2,4-oxadiazole moiety at C-5 through a straight-chain carbon and oxygen atoms. Eur. J. Med. Chem., 2009, 44(9), 3571-3576.
[17]
Rossi, L.L.; Basu, A. Glycosidase inhibition by 1-glycosyl-4-phenyl triazoles. Bioorg. Med. Chem. Lett., 2005, 15(15), 3596-3599.
[18]
Carvalho, I.; Andrade, P.; Campo, V.L.; Guedes, P.M.; Sesti-Costa, R.; Silva, J.S.; Schenkman, S.; Dedola, S.; Hill, L.; Rejzek, M.; Nepogodiev, S.A.; Field, R.A. ‘Click chemistry’ synthesis of a library of 1,2,3-triazole-substituted galactose derivatives and their evaluation against trypanosoma cruziand its cell surface trans-sialidase. Bioorg. Med. Chem., 2010, 18(7), 2412-2427.
[19]
Olomola, T.O.; Klein, R.; Lobb, K.A.; Sayed, Y.; Kaye, P.T. Towards the synthesis of coumarin derivatives as potential dual-action HIV-1 protease and reverse transcriptase inhibitors. Tetrahedron Lett., 2010, 51(48), 6325-6328.
[20]
da Silva, F.D.; de Souza, M.C.B.V.; Frugulhetti, I.I.P.; Castro, H.C.; Souza, S.L.D.; de Souza, T.M.L.; Rodrigues, D.Q.; Souza, A.M.T.; Abreu, P.A.; Passamani, F.; Rodrigues, C.R.; Ferreira, V.F. Synthesis, HIV-RT inhibitory activity and SAR of 1-benzyl-1H-1,2,3-triazole derivatives of carbohydrate. Eur. J. Med. Chem., 2009, 44(1), 373-383.
[21]
Mohite, P.B.; Bhaskar, V.H. Potential pharmacological activities of tetrazoles in the new millennium. Int. J. Pharm. Tech. Res., 2011, 3(3), 1557-1566.
[22]
Osheroff, N.; Zechiedrich, E.L.; Gale, K.C. Catalytic function of DNA topoisomerase II. BioEssays, 1991, 13(6), 269-275.
[23]
Issell, B.F. The podophyllotoxin derivatives VP16-213 and VM26. Cancer Chemother. Pharmacol., 1982, 7(2-3), 73-80.
[24]
Beers, S.A.; Imakura, Y.; Dai, H.J.; Li, D.H.; Cheng, Y.C.; Lee, K.H. Antitumor agents, 99. synthetic ring C aromatized podophyllotoxin analogues as potential inhibitors of human DNA topoisomerase II. J. Nat. Prod., 1988, 51(5), 901-905.
[25]
Day, S.H.; Lin, Y.C.; Tsai, M.L. Potent cytotoxic lignans from justicia procumbens and their effects on nitric oxide and tumor necrosis factor-α production in mouse macrophages. J. Nat. Prod., 2002, 65(3), 379-381.
[26]
Kumar, C.N.S.S.P.; Parida, D.K.; Santhoshi, A.; Kota, A.K.; Sridhar, B.; Rao, V.J. Synthesis and biological evaluation of tetrazole containing compounds as possible anticancer agents. MedChemComm, 2011, 2, 486-492.
[27]
Sammelson, R.E.; Miller, R.B.; Kurth, M.J. Linear tetraheterocycles composed of both bidentate diisoxazole and bidentate isoxazole-furyl/theinyl/pyridyl motifs. J. Org. Chem., 2000, 65(7), 2225-2228.
[28]
Ryng, S.; Glowiak, T. The isoxazole heterocyclic system: Synthesis of a new model structure in immunosuppressing agents. J. Chem. Crystallogr., 1998, 28(5), 373-378.
[29]
Herr, R.J. 5-substituted-1H-tetrazoles as carboxylic acid isosteres: Medicinal chemistry and synthetic methods. Bioorg. Med. Chem., 2002, 10(11), 3379-3392.
[30]
Master, H.E.; Khan, S.I.; Poojari, K.A. Design and synthesis of low molecular weight compounds with complement inhibition activity. Bioorg. Med. Chem., 2005, 13, 4891-4899.
[31]
El-Sayed, W.A.; Abdel Megeid, R.E.; Abbas, H.S. Synthesis and Antimicrobial Activity of New 1-[(tetrazol-5-yl)methyl]indole Derivatives, their 1,2,4-Triazole Thioglycosides and Acyclic Analogs. Arch. Pharm. Res., 2011, 34(7), 1085-1096.
[32]
Jordheim, L.P.; Durantel, D.; Zoulim, F.; Dumontet, C. Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. Nat. Rev. Drug Discov., 2013, 12, 447-464.
[33]
Gomha, S.M.; Ahmed, S.A.; Abdelhamid, A.O. Synthesis and cytotoxicity evaluation of some novel thiazoles, thiadiazoles, and Pyrido[2,3-d][1,2,4]triazolo[4,3-a]pyrimidin-5(1H)-ones incorporating triazole moiety. Molecules, 2015, 20, 1357-1376.
[34]
Dutta, S.; Ji Gupta, S.; Kumar Sen, A. Silver trifluoromethanesulfonate and metallic copper mediated syntheses of 1,2,3-triazole-O- and triazolyl glycoconjugates: consecutive glycosylation and cyclization under one-pot condition. Tetrahedron Lett., 2016, 57, 3086-3090.
[35]
dos Anjos, J.V.; Filho, R.A.W.N.; do Nascimento, S.C.; Srivastava, R.M.; de Melo, S.J.; Sinou, D. Synthesis and cytotoxic profile of glycosyl–triazole linked to 1,2,4-oxadiazole moiety at C-5 through a straight-chain carbon and oxygen atoms. Eur. J. Med. Chem., 2009, 44, 3571-3576.
[36]
El-Sayed, W.A.; El-Kosy, S.M.; Ali, O.M.; Emselm, H.M.; Abdel-Rahman, A.A. Anticancer activity of new (tetrazol-5-yl) methylindole derivatives and their acyclic c-nucleoside analogs. Acta Pol. Pharm., 2012, 69, 669-677.
[37]
Jedhe, G.S.; Paul, D.; Gonnade, R.G.; Santra, M.K.; Hamel, E.; Nguyen, T.L.; Sanjayan, G.J. Correlation of hydrogen-bonding propensity and anticancer profile of tetrazole-tethered combretastatin analogues. Bioorg. Med. Chem. Lett., 2013, 23, 4680-4684.
[38]
El-Sayed, W.A.; El-Sofany, W.I.; Mohamed, A.M.; Flefel, E.M.; Awad, H.M. Synthesis and anticancer activity of new 1-thia-4-azaspiro[4.5]decane, their derived thiazolopyrimidine and 1,3,4-thiadiazole thioglycosides. Molecules, 2017, 22, 170-179.
[39]
Mohamed, A.M.; Al-Qalawi, H.M.; El-Sayed, W.A.; Arafa, W.A.A.; Alhumamais, M.S.; Hassan, A.K. Acta Poloniae Pharmaceutica. Drug Res. , 2015, 72(2), 307-318.
[40]
Flefel, E.M.; Tantawy, W.A.; El-Sayed, W.A.; Sayed, H.H.; Fathy, N.M. Synthesis and anticancer activity of new substituted pyrazoles and their derived 1,2,4-Triazoles and their sugar derivatives. J. Heterocycl. Chem., 2013, 50, 344-350.
[41]
El-Sayed, W.A.; El-Sofany, W.I. Mohamed, Hussein H.A.; Fathi, N.M. Synthesis and anticancer activity of new [(Indolyl) pyrazolyl] -1,3,4-oxadiazole thioglycosides and acyclic nucleoside analogs. Nucleosides Nucleotides Nucleic Acids, 2017, 46, 474-495.
[42]
El-Sayed, W.A.; Rashad, A.E.; Awad, S.M.; Ali, M.M. Synthesis and in vitro anti-tumor activty of some new substituted thio pyrimidines through radical balnce regulation. Nucleosides Nucleotides Nucleic Acids, 2009, 28, 261-274.
[43]
Abbas, E.M.H.; Amin, K.M.; El-Hamouly, W.S.; Dawood, D.H.; Abdalla, M.M. Synthesis, anti-inflammatory and antinociceptive activity of some novel benzothiazole derivatives. Res. Chem. Intermed., 2015, 41, 2537-2555.
[44]
Amine, E.W.S.; Mahmoud, K.; Abbas, E.M.; Abdel-Maguid, H.; Ali, E. Synthesis and antimicrobial activity of some 3-substituted 5,6-dimethoxy-2,3-dihydrobenzo[d]thiazol-2-one. Chin. J. Chem., 2009, 27, 1629-1634.
[45]
Hamdy, N.A.; Anwar, M.M.; Abu-Zied, K.M.; Awad, H.M. Synthesis, tumor inhibitory and antioxidant activity of new polyfunctionally 2-substituted 5,6,7,8-tetrahydronaphthalene derivatives containing pyridine, thioxopyridine and pyrazolopyridine moieties. Acta Poloniae Pharmaceutica-Drug Res., 2013, 70(6), 987-1001.
[46]
Soliman, H.A.; Yousif, M.N.M.; Said, M.M.; Hassan, N.A.; Ali, M.M.; Awad, H.M.; Abdel-Megeid, F.M.E. Synthesis of novel 1,6-naphthyridines, pyrano[3,2-c]pyridines and pyrido[4,3-d]pyrimidines derived from 2,2,6,6-tetramethylpiperidin-4-one for in vitro anticancer and antioxidant evaluatio. Der. Pharma Chem., 2014, 6(3), 394-410.
[47]
Awad, H.M.; Abd-Alla, H.I.; Mahmoud, K.H.; El-Toumy, S.A. In vitro anti-nitrosative, antioxidant, and cytotoxicity activities of plant flavonoids: A comparative study. Med. Chem. Res., 2014, 23(7), 3298-3307.
[48]
Staker, B.L.; Feese, M.D.; Cushman, M.; Pommier, Y.; Zembower, D.; Stewart, L.; Burgin, A.B. Structure of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex. J. Med. Chem., 2005, 48, 2336-2345.
[49]
Kaminski, G.l.; Jorgensen, W.L. Performance of the AMBER94, MMFF94 and OPLS-AA forcefields for modeling organic liquids. J. Phys. Chem., 1996, 100, 18010-18013.
[50]
Lensink, M.F.; Méndez, R.; Wodak, S.J. Docking and scoring protein complexes:CAPRI 3rd Edition. Proteins,; , 2007, 69, pp. 704-718.